Log in

NASDAQ:DTILPrecision BioSciences Stock Price, Forecast & News

$8.28
+0.06 (+0.73 %)
(As of 07/8/2020 04:00 PM ET)
Add
Compare
Today's Range
$8.03
Now: $8.28
$8.73
50-Day Range
$7.01
MA: $7.80
$8.69
52-Week Range
$4.60
Now: $8.28
$23.67
Volume541,100 shs
Average Volume698,455 shs
Market Capitalization$429.40 million
P/E RatioN/A
Dividend YieldN/A
Beta1.73
Precision BioSciences, Inc. operates as a genome editing company and develops therapeutic products in the United States. It operates through two segments, Therapeutic and Food. The company offers ARCUS, a genome editing platform to cure cancers and genetic disorders. The Therapeutic segment develops allogeneic CAR T immunotherapy that recognizes and kills cancer cells; and engages in the in vivo gene correction activities. This segment develops PBCAR0191, is an allogeneic CAR T cell therapy targeting the tumor target CD19 for acute lymphoblastic leukemia and non-hodgkin lymphoma; and CD20, BCMA, and CLL-1, CAR T cell therapies targeting the tumor antigens. The Food segment develops food and nutrition products; and pre-breeding materials, a gene edited crop intermediate that could be integrated into breeding program and use in producing new crop varieties. The company has development and commercial license agreement with Shire Plc for research and development of individual T cell modifications; collaboration agreement with Gilead Sciences, Inc. to co-develop a product candidate to cure chronic Hepatitis B infection. Precision BioSciences, Inc. was founded in 2006 and is headquartered in Durham, North Carolina.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.4Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.61 out of 5 stars


Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:DTIL
CUSIPN/A
CIKN/A
Phone919-314-5512

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$22.24 million
Book Value$2.72 per share

Profitability

Net Income$-92,880,000.00
Net Margins-369.86%

Miscellaneous

Employees127
Market Cap$429.40 million
Next Earnings Date8/12/2020 (Estimated)
OptionableNot Optionable

Receive DTIL News and Ratings via Email

Sign-up to receive the latest news and ratings for DTIL and its competitors with MarketBeat's FREE daily newsletter.

Precision BioSciences (NASDAQ:DTIL) Frequently Asked Questions

How has Precision BioSciences' stock been impacted by COVID-19 (Coronavirus)?

Precision BioSciences' stock was trading at $6.49 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, DTIL shares have increased by 27.6% and is now trading at $8.28. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Precision BioSciences?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Precision BioSciences in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Precision BioSciences.

When is Precision BioSciences' next earnings date?

Precision BioSciences is scheduled to release its next quarterly earnings announcement on Wednesday, August 12th 2020. View our earnings forecast for Precision BioSciences.

How were Precision BioSciences' earnings last quarter?

Precision BioSciences Inc (NASDAQ:DTIL) announced its quarterly earnings data on Friday, May, 15th. The company reported ($0.52) EPS for the quarter, beating the Zacks' consensus estimate of ($0.53) by $0.01. The company had revenue of $7 million for the quarter, compared to analyst estimates of $5.20 million. Precision BioSciences had a negative return on equity of 60.32% and a negative net margin of 369.86%. View Precision BioSciences' earnings history.

What price target have analysts set for DTIL?

5 analysts have issued 12 month price objectives for Precision BioSciences' shares. Their forecasts range from $19.00 to $22.00. On average, they expect Precision BioSciences' share price to reach $20.67 in the next year. This suggests a possible upside of 149.6% from the stock's current price. View analysts' price targets for Precision BioSciences.

Has Precision BioSciences been receiving favorable news coverage?

News stories about DTIL stock have trended negative this week, InfoTrie Sentiment Analysis reports. The research firm rates the sentiment of media coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Precision BioSciences earned a media sentiment score of -2.1 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the company's share price in the near future. View the latest news about Precision BioSciences.

Are investors shorting Precision BioSciences?

Precision BioSciences saw a increase in short interest in the month of June. As of June 30th, there was short interest totaling 1,730,000 shares, an increase of 6.1% from the June 15th total of 1,630,000 shares. Based on an average trading volume of 571,700 shares, the days-to-cover ratio is presently 3.0 days. Approximately 4.9% of the company's shares are sold short. View Precision BioSciences' Current Options Chain.

Who are some of Precision BioSciences' key competitors?

What other stocks do shareholders of Precision BioSciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Precision BioSciences investors own include Editas Medicine (EDIT), Alector (ALEC), Gossamer Bio (GOSS), Alibaba Group (BABA), Inovio Pharmaceuticals (INO), Kaleido Biosciences (KLDO), Tcr2 Therapeutics (TCRR), Harpoon Therapeutics (HARP), Exxon Mobil (XOM) and Gilead Sciences (GILD).

Who are Precision BioSciences' key executives?

Precision BioSciences' management team includes the following people:
  • Mr. Matthew R. Kane, Co-Founder, CEO, Pres & Director (Age 42)
  • Dr. Derek Jantz Ph.D., Co-founder, Chief Scientific Officer & Director (Age 43)
  • Dr. Jefferson J. Smith Ph.D., Co-Founder & CTO
  • Mr. Abid Ansari, Chief Financial Officer (Age 41)
  • Ms. Molly Lukes PHR, SHRM-CP, Director of HR

When did Precision BioSciences IPO?

(DTIL) raised $126 million in an initial public offering on Thursday, March 28th 2019. The company issued 7,900,000 shares at $15.00-$17.00 per share. J.P. Morgan, Goldman Sachs, Jefferies and Barclays served as the underwriters for the IPO.

What is Precision BioSciences' stock symbol?

Precision BioSciences trades on the NASDAQ under the ticker symbol "DTIL."

Who are Precision BioSciences' major shareholders?

Precision BioSciences' stock is owned by many different institutional and retail investors. Top institutional shareholders include Thomasville National Bank (0.13%). Company insiders that own Precision BioSciences stock include Christopher Heery, Global Strategic Fund Venbio and Tony Dung Ling Yao. View institutional ownership trends for Precision BioSciences.

Which institutional investors are buying Precision BioSciences stock?

DTIL stock was purchased by a variety of institutional investors in the last quarter, including Thomasville National Bank. Company insiders that have bought Precision BioSciences stock in the last two years include Christopher Heery, Global Strategic Fund Venbio, and Tony Dung Ling Yao. View insider buying and selling activity for Precision BioSciences.

How do I buy shares of Precision BioSciences?

Shares of DTIL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Precision BioSciences' stock price today?

One share of DTIL stock can currently be purchased for approximately $8.28.

How big of a company is Precision BioSciences?

Precision BioSciences has a market capitalization of $429.40 million and generates $22.24 million in revenue each year. The company earns $-92,880,000.00 in net income (profit) each year or ($1.91) on an earnings per share basis. Precision BioSciences employs 127 workers across the globe.

What is Precision BioSciences' official website?

The official website for Precision BioSciences is www.precisionbiosciences.com.

How can I contact Precision BioSciences?

Precision BioSciences' mailing address is 302 EAST PETTIGREW STREET SUITE A-100, DURHAM NC, 27701. The company can be reached via phone at 919-314-5512 or via email at [email protected]

This page was last updated on 7/9/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.